Literature DB >> 2462307

Construction and use of a safe and efficient amphotropic packaging cell line.

D Markowitz1, S Goff, A Bank.   

Abstract

An amphotropic retrovirus packaging cell line was constructed in which the gag, pol, and env genes of the helper virus are separated on two different plasmids and in which the packaging signals and 3' long terminal repeats are removed. To do this, a plasmid containing the Moloney murine leukemia virus gag and pol gene was transfected into NIH 3T3 cells, and a plasmid containing the 4070A amphotropic env gene was transfected into one of the resulting clones which produced a high level of reverse transcriptase. A clone producing a high level of amphotropic env protein (GP + envAm12) was then isolated. When transfected into GP + envAm12 cells, titers of the retroviral vector N2, containing a neomycin resistance gene, ranged from 10(2) to greater than 10(6) CFU/ml on 3T3 cells, from 1.3 x 10(4) to 2.7 x 10(5) CFU/ml on HeLa cells, and from 1.0 x 10(2) to 6.0 x 10(3) CFU/ml on K562 cells when assayed by G418 resistance. These titers were comparable to titers obtained using the PA317 cell line. Tests for the safety of the GP + envAm12 packaging line showed no evidence for the generation of wild-type virus. Thus, the efficiency and safety of the GP + envAm12 cell line in gene transfer into human cells may provide an optimal system for experiments whose goal is human gene therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2462307

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  134 in total

1.  A GATA-2/estrogen receptor chimera functions as a ligand-dependent negative regulator of self-renewal.

Authors:  C Heyworth; K Gale; M Dexter; G May; T Enver
Journal:  Genes Dev       Date:  1999-07-15       Impact factor: 11.361

2.  Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function.

Authors:  Paola Matarrese; Luigi Di Biase; Laura Santodonato; Elisabetta Straface; Monica Mecchia; Barbara Ascione; Giorgio Parmiani; Filippo Belardelli; Maria Ferrantini; Walter Malorni
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

3.  Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection.

Authors:  G Gao; S P Goff
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

4.  A virus-virus interaction circumvents the virus receptor requirement for infection by pathogenic retroviruses.

Authors:  David L Wensel; Weihua Li; James M Cunningham
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

5.  Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection.

Authors:  A L Barnett; R A Davey; J M Cunningham
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

6.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

7.  Improved retroviral vectors for gene transfer and expression.

Authors:  A D Miller; G J Rosman
Journal:  Biotechniques       Date:  1989-10       Impact factor: 1.993

Review 8.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

9.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy.

Authors:  J G Julias; D Hash; V K Pathak
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.